Adelis Equity Partners Acquires Majority Stake in IonOpticks
September 10, 2024
Adelis Equity Partners has taken a majority, controlling stake in IonOpticks, a fast-growing developer and manufacturer of high-performance chromatography solutions for LC‑MS proteomics. The founders and management are co-investors; the investment will fund IonOpticks' global expansion, product development, and support future acquisitions as the company scales its commercial footprint.
- Buyers
- Adelis Equity Partners
- Targets
- IonOpticks
- Industry
- Biotechnology
- Location
- Victoria, Australia
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.